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Chylous ascites (CA) is the extravasation of lipid-rich lymphatic fluid into the peritoneal
space following trauma or obstruction of the lymphatic system. Refractory cases of
cirrhosis-related CA may be amendable to transjugular intrahepatic portosystemic
shunting (TIPS). We present a case of TIPS in the setting of refractory CA secondary to
cirrhosis of a transplanted liver graft. Following TIPS, the patient reported immediate
improvement in abdominal pain and no longer requires paracentesis. Our case suggests
TIPS to be a safe and effective treatment option for CA in liver transplant patients with
cirrhosis.
© 2016 Published by Elsevier Inc. on behalf of under copyright license from the University of
Washington. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Chylous ascites (CA) is a rare form of ascites defined as the
extravasation of lipid-rich lymphatic fluid into the peritoneal
cavity [1]. Disruption of the lymphatic system secondary to
traumatic injury or obstruction produces CA, which is turbid
or milky in appearance from high triglyceride levels, usually
more than 1.10 kg/m3 [1,2]. Intra-abdominal malignancies and
cirrhosis account for two-thirds of all cases in developed
countries, whereas infection (e.g., tuberculosis) is the
predominant cause in the developing world [3]. CA can alsor AngioDynamics, Inc. Th
(F.J. Gortes).
on behalf of under copyr
se (http://creativecommooccur following orthotopic liver transplantation (LT), particu-
larly in patientswith preoperative ascites [4]. Treatment of the
underlying cause is crucial. Conservative medical manage-
ment of CA includes a high-protein low-fat diet and thera-
peutic paracentesis [1]. Resistant cases may be amendable to
peritoneovenous shunting and transjugular intrahepatic
portosystemic shunting (TIPS). TIPS is reserved for cirrhosis-
related CA; however, its use in cirrhosis of a transplanted
liver graft has not beenwell documented. A patient is reported
with refractory CA and cirrhosis after LT, in whom the CAwas
treated with TIPS.e other authors have declared that no competing interests exist.
ight license from the University of Washington. This is an open
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A 55-year-oldmale with a history of orthotopic LT 10 years ago
for hepatitis C virus (HCV)einduced cirrhosis was referred to
interventional radiology for management of resistant ascites.
He developed recurrent HCV cirrhosis of the transplanted liver
which was confirmed by liver biopsy (grade 2 stage III
cirrhosis). Subsequently, the patient developed persistent CA.
Splenic artery embolization was performed 3 years ago to
control the ascites, but the patient had only minimal
improvement in ascites volume. Two years ago, he underwent
hepatic lymphangiography which demonstrated an amor-
phous area communicating with the hepatic veins and
lymphatic channels (Fig. 1). The area was embolized with
approximately 0.3mL of the Onyx Liquid Embolization System
(Medtronic, Minneapolis, MN). Notwithstanding, he continued
to require weekly therapeutic paracenteses and presented
multiple times to the emergency department with intractable
abdominal pain. Ascitic fluid was always milky and consis-
tently showed normal lymphocyte, neutrophil, and erythro-
cyte counts; and elevated triglyceride levelsdranging from
2.39e3.06 kg/m3ddiagnostic of CA. Additionally, the ascites to
plasma triglyceride ratio was consistently elevated (greater
than 5:1). Furosemide, aldactone, and a low-fat diet supple-
mented withmedium-chain triglycerides were tried but failed
to alleviate the CA. He was ultimately referred for TIPS
creation.
Before TIPS placement, paracentesis was done and drained
3 L of CA. Next, the right internal jugular vein was accessed,
and the right hepatic vein was cannulated. The venous pres-
sures were measured, and portosystemic gradient was 13mm
Hg. A CO2-wedged porto-venogram showed a patent PV. The
right PV was next accessed with a Rosch-Uchida needle (Cook
Medical, Bloomington, IN). The parenchymal tract was dilated
with an 8mm 8 cmballoon and a 10mm 9 cmViatorr stentFig. 1 e Hepatic lymphangiogram showing amorphous
collection lymphatic structures (bottom arrow)
communicating with hepatic veins (top arrow) and
lymphatic channels.(Gore, Newark, DE) was then placed (Fig. 2). Porto-venogram
after stent placement demonstrated brisk shunting between
the PV and the right atrium. Post-TIPS portosystemic gradient
was 1 mm Hg. After the procedure, the patient reported
improvement in abdominal pain and fullness. Weekly para-
centeses were performed up to 2 months after TIPS, but the
volumes consistently decreased. Three months after the
procedure, the patient did not require therapeutic
paracentesis.Discussion
CA is uncommon, accounting for only 0.5%e1% of cirrhosis-
related ascites [5]. Spontaneous rupture of the serosal
lymphatic channels, secondary to excessive lymph flow, is
thought to cause CA in cirrhosis [5]. Hepatic lymph flow
increases in cirrhosis due to increased pressure gradient
between the capillaries and interstitial compartments of the
liver [5]. The pressure gradient itself increases secondary to
cirrhosis-induced sinusoidal and post-sinusoidal portal
hypertension (PH) [5]. Moreover, PH results in splanchnic
venous congestion, which increases gastrointestinal
lymphatic flow [5].
The incidence of CA in LT patients is similar to that of non-
LT patients. In a study of 516 LT patients, 24 developed CA
(0.5%) [4]. CA occurs after LT through two separate, or com-
bined,mechanisms. Onemechanism, as previously described,
involves increased lymph production and flow secondary to
cirrhosis [4]. The second mechanism pertains to intra-
operative injury of periportal and retrohepatic lymphatic
vessels and inadequate ligation of the damaged vessels [4]. InFig. 2 e Portal venogram demonstrating patency of the
intraparenchymal tract and visualization of Viatorr stent.
Note donor inferior vena cava stump (arrow).
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(Medtronic, Minneapolis, MN) vessel sealing system (as
opposed to conventional suture ligation) are independent risk
factors for the development of CA after LT [4].
Studies addressing the optimal treatment of CA are limited
[3]. However, a stepwise approachdescalating from conser-
vative medical management to invasive proceduresdis the
consensus [5]. Most patients respond initially to a high-protein
and low-fat diet with medium-chain triglycerides (MCT) [3].
The restriction of long-chain triglycerides minimizes the
breakdown of these into monoglycerides and free fatty acids
(FFAs), which are carried in chylomicrons through the intes-
tinal lymphatic ducts [3]. In contrast, MCTs are converted to
FFAs and glycerol and transported directly from the intestines
to the liver via the portal vein, never entering the lymphatic
system [3]. Thus, a low-fat diet supplemented with MCTs de-
creases the production and flow of chyle [3]. Cirrhosis-induced
CA is also amendable to sodium restriction and diuretics [3]. If
patients do not respond, bowel rest and total parenteral
nutrition may be necessary [3]. Additionally, therapeutic
paracentesis can provide immediate and significant relief of
dyspnea and abdominal pain, although prolonged drainage
can result in electrolyte imbalances and infection [3,5].
If cirrhosis-related CA fails to respond to the above mea-
sures, TIPS creation may provide symptomatic improvement
[5]. The mechanism by which TIPS ameliorates CA is unclear,
although it may be the result of diminished hepatic and
gastrointestinal lymph flow secondary to decreased portal
venous pressures [5]. Tsauo et al. reported a case of TIPS for
the treatment of CA (and chylothorax) and conducted a
systematic review of the literature; all ten patients reported in
the study experienced improvement in CA after TIPS.However, none of the reported patients had undergone liver
transplantation.
Our case is the first reported of TIPS for the treatment of CA
following LT. TIPS creation was a technical success without
any postoperative complications, and improved CA signifi-
cantly, eliminating the need for weekly therapeutic
paracentesis. TIPS was most likely successful because it
addressed cirrhosis-related CA. It is unclear whether TIPS
would alleviate CA resulting from damage to the lymphatic
system during transplant surgery. For such cases, percuta-
neous lymph vessel embolization may be more appropriate.
To conclude, TIPS may be an effective and safe treatment for
medically refractory CA in LT patients with cirrhosis.r e f e r e n c e s
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